7 ANNEX VII COMMON SPECIFICATIONS FOR DEVICES INTENDED FOR DETECTION OR QUANTIFICATION OF MARKERS OF HEPATITIS D VIRUS (HDV) INFECTION, Regulation (EU) 2022/1107

In forcesince 4 Jul 2022

This Annex applies to devices intended for detection or quantification of markers of hepatitis D virus (HDV) infection.

Table 1 applies to devices intended for detection (including confirmation) or quantification of the following hepatitis D virus markers: antibodies against hepatitis D virus (anti-HDV), IgM antibodies against hepatitis D virus (anti-HDV IgM), the delta antigen.

Table 2 applies to qualitative and quantitative NAT devices for HDV RNA.

Performance characteristic | | anti-HDV | anti-HDV IgM | Delta antigen | Acceptance criteria

Diagnostic sensitivity | Positive specimens |

≥100

Specifying markers of HBV coinfection

≥50

Specifying markers of HBV coinfection

≥10

Specifying markers of HBV coinfection

≥ 98 %

Diagnostic specificity | Negative specimens |

≥200

Including clinical specimens

≥50 potentially interfering specimens

≥200

Including clinical specimens

≥50 potentially interfering specimens

≥200

Including clinical specimens

≥50 potentially interfering specimens

≥ 98 %

1.

For target sequence amplification devices, a functionality control for each specimen (internal control) shall reflect the state of the art. This control shall as far as possible be used throughout the whole process, i.e. extraction, amplification/hybridisation, detection.

2.

Genotype and/or subtype detection shall be demonstrated by appropriate primer or probe design validation and shall also be validated by testing characterised genotyped specimens.

3.

Potential cross-reactivity of non-target nucleic acid sequences shall be analysed by appropriate primer or probe design validation and shall also be validated by testing selected specimens.

4.

Results of quantitative NAT devices shall be traceable to international standards or calibrated reference materials, if available, and be expressed in international units utilised in the specific field of application.

[Reference: European Pharmacopeia 9.0, 2.6.21 Nucleic acid amplification techniques, Validation.]

Performance characteristic | Specimen | Specimen numbers, features, use | Acceptance criteria

Analytical sensitivity | WHO First International Standard HDV RNA, PEI code 7657/12 |

NAT sensitivity and NAT LOD shall be validated by dilution series of reference materials, testing of replicates (minimum 24) at different analyte concentrations, including those with transition from positive to negative results with the respective NAT device.

LOD shall be expressed as 95% positive cut-off value (IU/ml) after statistical analysis (e.g. Probit).

quantitative NAT: definition of lower, upper quantification limit, precision, accuracy,

‘linear’ measuring range, ‘dynamic range’. Reproducibility at different concentration levels

According to the state of the art

HDV genotype sensitivity |

all relevant genotypes/subtypes, preferably from international reference materials

potential substitutes for rare HDV genotypes (to be quantified by appropriate methods): plasmids; synthetic RNA

Quantitative NAT: dilution series for demonstration of quantification efficiencies | According to the state of the art

Diagnostic specificity | Blood donor specimens |

Qualitative NAT: ≥100

Quantitative NAT: ≥100

According to the state of the art

Cross-reactivity | Potentially cross-reacting specimens | | According to the state of the art

Carry-over |

High HDV RNA positive;

HDV RNA negative

At least five runs with alternating high-positive and negative specimens shall be performed during robustness studies. The virus titres of the high positive specimens shall be representative of high virus titres occurring naturally. | According to the state of the art

Whole system failure rate | HDV RNA low-positive | ≥100 HDV RNA low-positive specimens shall be tested. These specimens shall contain a virus concentration equivalent to three times the 95 % positive cut-off virus concentration. | ≥99% positive